# General

**Common Present on Admission Diagnosis** 

] Acidosis	Details
] Acute Post-Hemorrhagic Anemia	Details
] Acute Renal Failure	Details
] Acute Respiratory Failure	Details
] Acute Thromboembolism of Deep Veins of Lower Extremities	Details
] Anemia	Details
] Bacteremia	Details
] Bipolar disorder, unspecified	Details
Cardiac Arrest	Details
Cardiac Dysrhythmia	Details
Cardiogenic Shock	Details
Decubitus Ulcer	Details
Dementia in Conditions Classified Elsewhere	Details
Disorder of Liver	Details
Electrolyte and Fluid Disorder	Details
Intestinal Infection due to Clostridium Difficile	Details
Methicillin Resistant Staphylococcus Aureus Infection	Details
Obstructive Chronic Bronchitis with Exacerbation	Details
Other Alteration of Consciousness	Details
Other and Unspecified Coagulation Defects	Details
Other Pulmonary Embolism and Infarction	Details
Phlebitis and Thrombophlebitis	Details
Protein-calorie Malnutrition	Details
Psychosis, unspecified psychosis type	Details
Schizophrenia Disorder	Details
	Details
] Sepsis	
Septic Shock	Details
Septicemia	Details
] Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled	Details
] Urinary Tract Infection, Site Not Specified	Details
dmission or Observation (Single Response)	
) Admit to Inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgme
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital services for two or more midnights.
Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
	Patient Condition:
	Bed request comments:
) Outpatient in a bed - extended recovery	Diagnosis:
-	Admitting Physician:
	Bed request comments:
Admission or Observation (Single Response) Patient has active status order on file	

Patient has active status order on file

() Admit to Inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments: Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
() Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
	Patient Condition:
	Bed request comments:
() Outpatient in a bed - extended recovery	Diagnosis:
()	Admitting Physician:
	Bed request comments:
Admission (Single Response) Patient has active status order on file.	
() Admit to inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgmen
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
Code Status	
[] Full code	Code Status decision reached by:
[] <u>DNR</u>	
[] DNR (Do Not Resuscitate)	Does patient have decision-making capacity?
[] Consult to Palliative Care Service	Priority:
	Reason for Consult?
	Order?
	Name of referring provider:
	Enter call back number:
[] Consult to Social Work	Reason for Consult:
[] Modified Code	Does patient have decision-making capacity?
	Modified Code restrictions:
[] Treatment Restrictions	Treatment Restriction decision reached by: Specify Treatment Restrictions:
Isolation	
Airborne isolation status	Details
Contact isolation status	Details
	Details
[] Droplet isolation status         [] Enteric isolation status	Details
Precautions	
[] Aspiration precautions	Details
[] Fall precautions	Increased observation level needed:
Latex precautions	Details
Latex precautions     Seizure precautions	Increased observation level needed:
Nursing	

Vital Signs

[] Vital signs - T/P/R/BP per unit protocol	Routine, Per unit protocol
Activity	
[] Ambulate	Routine, 3 times daily Specify:
[] Ambulate as tolerated	Routine, 3 times daily Specify:
] Strict bed rest	Routine, Until discontinued, Starting S May elevate Head of Bed 30 degrees.
Nursing	
[] Telemetry	"And" Linked Panel
[] Telemetry monitoring	Routine, Continuous Order: Place in Centralized Telemetry Monitor: EKG Monitoring Only (Telemetry Box) Reason for telemetry: Can be off of Telemetry for tests and baths? Yes
[] Telemetry Additional Setup Information	Routine, Continuous High Heart Rate (BPM): 120 Low Heart Rate(BPM): 50 High PVC's (per minute): 10 High SBP(mmHg): 175 Low SBP(mmHg): 100 High DBP(mmHg): 95 Low DBP(mmHg): 40 Low Mean BP: 60 High Mean BP: 120 Low SPO2(%): 94
[] Place TED hose	Routine, Once
<ul> <li>[] Collect initial labs before starting anticoagulation.</li> <li>[] Height and weight</li> <li>Notify</li> </ul>	Routine, Once For 1 Occurrences Routine, Once For 1 Occurrences On Admission.
[] Notify Physician of following vitals	Routine, Until discontinued, Starting S, Systolic BP GREATEF than 180 mmHg Systolic BP LESS than 80 mmHg Heart rate GREATER than 120 bpm Heart rate LESS than 55 bpm SpO2 LESS than 90
[] NPO	Diet effective now, Starting S NPO:

[] NPO	Diet effective now, Starting S	
	NPO:	
	Pre-Operative fasting options:	
[] Diet - Regular	Diet effective now, Starting S	
	Diet(s): Regular, Other Potass/Phos	
	Potassium/Phosphorus: 2 GM Potassium	
	Advance Diet as Tolerated?	
	Liquid Consistency:	
	Fluid Restriction:	
	Foods to Avoid:	
	Low Vitamin K	
[] Diet - 2000 Kcal/225 gm Carb	Diet effective now, Starting S	
	Diet(s): 2000 Kcal/225 gm Carbohydrate	
	Advance Diet as Tolerated?	
	Liquid Consistency:	
	Fluid Restriction:	
	Foods to Avoid:	

[] Diet - Heart healthy	Diet effective now, Starting S Diet(s): Heart Healthy Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction:
[] Diet	Foods to Avoid: Diet effective now, Starting S Diet(s): Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction:
IV Fluids	Foods to Avoid:
V Fluids	
] sodium chloride 0.45 % infusion	intravenous, continuous
[] sodium chloride 0.9 % infusion	intravenous, continuous
Medications	
Low Molecular Weight Heparins	
[] enoxaparin (LOVENOX) injection (Single Response)	
() CrCl greater than or equal to 30 mL/min	1 mg/kg, subcutaneous, 2 times daily at 0600, 1800 (time critical)
() CrCl less than 30 mL/min	1 mg/kg, subcutaneous, daily at 1700 (time critical)
Vitamin K Antagonists (Single Response)	
) warfarin (COUMADIN) with consult and labs	
[] warfarin (COUMADIN) tablet	oral, once, S at 5:00 PM, For 1 Doses
[] Pharmacy consult to manage warfarin (COUMADIN)	Routine, Until discontinued, Starting S Indication:
[] Prothrombin Time/INR STAT	STAT, Starting S For 1 Occurrences
[] Prothrombin Time/INR AM Draw	AM draw, Starting S+1 For 1 Occurrences
[] Prothrombin Time/INR every 72 hours	Every 72 hours, Starting S+1
) warfarin (COUMADIN) with consult and labs	
[] warfarin (COUMADIN) tablet	oral, once, S at 5:00 PM, For 1 Doses Indication:
[] Pharmacy consult to manage warfarin (COUMADIN)	Routine, Until discontinued, Starting S Indication:
[] Prothrombin Time/INR STAT	STAT, Starting S For 1 Occurrences
Prothrombin Time/INR every 72 hours	Every 72 hours, Starting S+1
() warfarin (COUMADIN) with labs	
[] warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
[] Prothrombin Time/INR STAT	STAT, Starting S For 1 Occurrences
Prothrombin Time/INR AM Draw	AM draw, Starting S+1 For 1 Occurrences
[] Prothrombin Time/INR every 72 hours	Every 72 hours, Starting S+1
() warfarin (COUMADIN) with labs	
[] warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
[] Prothrombin Time/INR STAT	STAT, Starting S For 1 Occurrences
[] Prothrombin Time/INR every 7 days	Weekly, Starting S+1
Heparin (Single Response)	
() Pharmacy to dose heparin	Routine, Until discontinued, Starting S Heparin Indication: Specify: Monitoring: Anti-Xa

() heparin infusion 50 units/mL in dextrose 5%	intravenous, continuous Indication:
	Therapeutic Monitoring Target:
Direct Xa Inhibitors (Single Response)	
() rivaroxaban (XARELTO) initial therapy and maintenance	"And" Linked Panel
[] rivaroxaban (XARELTO) tablet	15 mg, oral, 2 times daily at 0900, 1700 (time critical), For 21 Days Indications: DVT/PE
[] Pharmacy consult to monitor rivaroxaban (XARELTO) therapy	STAT, Until discontinued, Starting S Indication:
[] rivaroxaban (XARELTO) tablet	20 mg, oral, daily at 1700 (time critical), Starting H+504 Hours Indications: DVT/PE
() apixaban (ELIQUIS) initial therapy and maintenance	"And" Linked Panel
[] apixaban (ELIQUIS) tablet	10 mg, oral, 2 times daily, For 7 Days Indications: DVT/PE
<ul> <li>Pharmacy consult to monitor apixaban (ELIQUIS) therapy</li> </ul>	STAT, Until discontinued, Starting S
[] apixaban (ELIQUIS) tablet	5 mg, oral, 2 times daily, Starting S+7 Indications: DVT/PE
<ul> <li>dabigatran (PRADAXA) therapy - after 5 days of parenteral anticoagulation</li> </ul>	"And" Linked Panel
[] dabigatran etexilate (PRADAXA) capsule	150 mg, oral, 2 times daily Indications: DVT/PE
[] Pharmacy consult to monitor dabigatran (PRADAXA) therapy	STAT, Until discontinued, Starting S
Analgesics	
[] acetaminophen (TYLENOL) oral/rectal	"Or" Linked Panel
[] acetaminophen (TYLENOL) tablet	325 mg, oral, every 4 hours PRN, fever Maximum dose of 3,000 mg per day (total from all sources).
[] acetaminophen (TYLENOL) suppository	325 mg, rectal, every 4 hours PRN, fever Maximum dose of 3,000 mg per day (total from all sources). For rectal use only.
VTE	
DVT Risk and Prophylaxis Tool (Single Response)	

DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

() Low Risk of DVT

[] Low Risk (Single Response)

() Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed.
	Will encourgae early ambulation
) Moderate Risk of DVT - Surgical	
Address pharmacologic prophylaxis by selecting one of the foll pharmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min</li> </ul>	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min</li> </ul>	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily, Starting S+1</li> <li>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.</li> <li>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):</li> </ul>
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
<ul> <li>heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li> </ul>	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once

[] Place antiembolic stockings () Moderate Risk of DVT - Non-Surgical

Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated.

Moderate Risk     Moderate risk of VTE	Routine, Once
Moderate Risk Pharmacological Prophylaxis -	
Non-Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is
	already on therapeutic anticoagulation for other indication.
	Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once
	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	10 mm automacus deily et 1700 (time aritical). Startin
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Startin S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL	30 mg, subcutaneous, daily at 1700 (time critical), Startin
LESS than 30 mL/min	S
	For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily, Starting S
between 100-139 kg and CrCl GREATER than 30	For Patients weight between 100-139 kg and CrCl
mL/min	GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, 2 times daily, Starting S
140 kg or GREATER and CrCl GREATER than 30	For Patients weight 140 kg or GREATER and CrCl
mL/min	GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
	If the patient does not have a history of or suspected case
	of Heparin-Induced Thrombocytopenia (HIT), do NOT ord
	this medication. Contraindicated in patients LESS than
	50kg, prior to surgery/invasive procedure, or CrCl LESS
	than 30 mL/min This patient has a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
with high risk of bleeding, e.g. weight < 50kg and age >	Recommended for patients with high risk of bleeding, e.g.
75yrs)	weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical)
	Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S
	Indication:
] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once
	No mechanical VTE prophylaxis due to the following
	contraindication(s):
() Place/Maintain sequential compression device	Routine, Continuous
continuous	
() Place sequential compression device and antiembolic	"And" Linked Panel
stockings	Deutine Centinueur
[] Place/Maintain sequential compression device	Routine, Continuous
continuous	Douting Ones
[] Place antiembolic stockings	Routine, Once
High Risk of DVT - Surgical	devine from Dharmonological and Machanical Drark-device
Address both pharmacologic and mechanical prophylaxis by ore	dening from Pharmacological and Mechanical Prophylaxis.
] High Risk	
J High risk of VTE	Routino Onco

Routine, Once

[] High risk of VTE

[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)

() Patient is currently receiving therapeutic anticoagulation	Poutino Oneo
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.
() Contraindications evict for phormacologic prophylovic	Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Startin S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Startin S+1 For Patients with CrCL LESS than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min</li> </ul>	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min</li> </ul>	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily, Starting S+1</li> <li>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.</li> <li>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):</li> </ul>
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
<ul> <li>heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li> </ul>	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings High Risk of DVT - Non-Surgical	Routine, Once
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
<ul> <li>[] High risk of VTE</li> <li>[] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)</li> </ul>	Routine, Once
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:

() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) njetion (ongle nesponse) () enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S
	For Patients with CrCL LESS than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min</li> </ul>	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min</li> </ul>	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily</li> <li>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.</li> <li>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):</li> </ul>
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
<ul> <li>() heparin (porcine) injection</li> <li>() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li> </ul>	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
() High Risk of DVT - Surgical (Hip/Knee) Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Response)	

(	) enoxaparin (LOVENOX) syringe - hip arthoplasty	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
(	) enoxaparin (LOVENOX) syringe - knee arthroplasty	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
(	) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min.
$\overline{I}$	) analyze and the second s	
(	) enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
(	) enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
$\overline{()}$	rivaroxaban (XARELTO) tablet for hip or knee	10 mg, oral, daily at 0600 (time critical), Starting S+1
()	arthroplasty planned during this admission	To be Given on Post Op Day 1. Indications:
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[]	Mechanical Prophylaxis (Single Response)	
	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
()	Place/Maintain sequential compression device continuous	Routine, Continuous
()	Place sequential compression device and antiembolic stockings	"And" Linked Panel
[	] Place/Maintain sequential compression device continuous	Routine, Continuous
[	] Place antiembolic stockings	Routine, Once

DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition Both pharmacologic AND mechanical prophylaxis must be addressed. Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions: Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders) Age 60 and above Severe fracture of hip, pelvis or leg Central line Acute spinal cord injury with paresis History of DVT or family history of VTE Multiple major traumas Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER Less than fully and independently ambulatory Acute ischemic stroke Estrogen therapy History of PE Moderate or major surgery (not for cancer) Major surgery within 3 months of admission () Low Risk of DVT [] Low Risk (Single Response) () Low risk of VTE Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation () Moderate Risk of DVT - Surgical Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated. [] Moderate Risk [] Moderate risk of VTE Routine, Once [] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once () Contraindications exist for pharmacologic prophylaxis No pharmacologic VTE prophylaxis due to the following contraindication(s): () enoxaparin (LOVENOX) injection (Single Response) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL 30 mg, subcutaneous, daily at 0600 (time critical), Starting LESS than 30 mL/min S+1 For Patients with CrCL LESS than 30 mL/min enoxaparin (LOVENOX) syringe - For Patients weight 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time () between 100-139 kg and CrCl GREATER than 30 critical), Starting S+1 mL/min For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time 140 kg or GREATER and CrCl GREATER than 30 critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl mL/min

GREATER than 30 mL/min

than 30 mL/min.

2.5 mg, subcutaneous, daily, Starting S+1

This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):

If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS

() fondaparinux (ARIXTRA) injection

() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age >	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM
75yrs)	Recommended for patients with high risk of bleeding, e.g.
	weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Moderate Risk of DVT - Non-Surgical	
Address pharmacologic prophylaxis by selecting one of the follo pharmacologic prophylaxis is contraindicated.	wing. Mechanical prophylaxis is optional unless
] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
<ul> <li>Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)</li> </ul>	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Startin S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL	30 mg, subcutaneous, daily at 1700 (time critical), Startin
LESS than 30 mL/min	S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, every 12 hours at 0900, 2100 (time
between 100-139 kg and CrCI GREATER than 30	critical), Starting S+1
mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, every 12 hours at 0900, 2100 (time
140 kg or GREATER and CrCl GREATER than 30	critical), Starting S+1
mL/min	For Patients weight 140 kg or GREATER and CrCl
	GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
	If the patient does not have a history of or suspected case
	of Heparin-Induced Thrombocytopenia (HIT), do NOT ordet this medication. Contraindicated in patients LESS than
	50kg, prior to surgery/invasive procedure, or CrCI LESS
	than 30 mL/min
	This patient has a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
with high risk of bleeding, e.g. weight < 50kg and age >	Recommended for patients with high risk of bleeding, e.g.
75yrs)	weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
High Risk of DVT - Surgical	dering from Pharmacological and Mechanical Prophylaxis.
Address both pharmacologic and mechanical prophylaxis by orc	
] High Risk	
	Routine, Once

() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min</li> </ul>	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min</li> </ul>	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily, Starting S+1</li> <li>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.</li> <li>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):</li> </ul>
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
<ul> <li>heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li> </ul>	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
() High Risk of DVT - Non-Surgical	
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily, Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily, Starting S+1 For Patients with CrCL LESS than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min</li> </ul>	30 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min

() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30	40 mg, subcutaneous, every 12 hours at 0900, 2100 (tim critical)
mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
	If the patient does not have a history of or suspected case
	of Heparin-Induced Thrombocytopenia (HIT) do NOT orde
	this medication. Contraindicated in patients LESS than
	50kg, prior to surgery/invasive procedure, or CrCI LESS
	than 30 mL/min.
	This patient has a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical)
	Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S
	Indication:
High Risk of DVT - Surgical (Hip/Knee)	
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Hip or Knee	
(Arthroplasty) Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is

	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe - hip arthoplasty	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - knee arthroplasty	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min.
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min</li> </ul>	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min</li> </ul>	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):

()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
$\overline{()}$	heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00
	with high risk of bleeding, e.g. weight < 50kg and age >	AM
	75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
$\overline{()}$	rivaroxaban (XARELTO) tablet for hip or knee	10 mg, oral, daily at 0600 (time critical), Starting S+1
()	arthroplasty planned during this admission	To be Given on Post Op Day 1. Indications:
$\overline{()}$	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1
()		Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
	isk and Prophylaxis Tool (Single Response)	
	Risk Definition Moderate Risk Definition	
	rmacologic prophylaxis must be addressed. Mechanical pro	phylaxis is optional unless pharmacologic is
	traindicated. High Risk Definition	
	h pharmacologic AND mechanical prophylaxis must be addr	
	eless than 60 years and NO other VTE risk factors One or m	nore of the following medical conditions: One or more of the
	wing medical conditions:	
	ent already adequately anticoagulated CHF, MI, lung diseas	
	is, cancer, sepsis, obesity, previous stroke, rheumatologic d	
	sis and nephrotic syndrome Thrombophilia (Factor V Leiden,	
	drome; antithrombin, protein C or protein S deficiency; hype	rhomocysteinemia; myeloproliferative disorders)
	e 60 and above Severe fracture of hip, pelvis or leg	
	ntral line Acute spinal cord injury with paresis	
	story of DVT or family history of VTE Multiple major traumas	
Λn		
	ticipated length of stay GREATER than 48 hours Abdominal	l or pelvic surgery for CANCER
Le	ss than fully and independently ambulatory Acute ischemic s	l or pelvic surgery for CANCER
Le Es	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE	l or pelvic surgery for CANCER
Le Es Mo	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer)	l or pelvic surgery for CANCER
Le Es Mo	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE	l or pelvic surgery for CANCER
Le Es Mo	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer)	l or pelvic surgery for CANCER
Le Es Mo Ma	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT	l or pelvic surgery for CANCER
Le Es Ma Ma	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response)	I or pelvic surgery for CANCER stroke
Le Es Mo Ma	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT	I or pelvic surgery for CANCER stroke Routine, Once
Le Es Mo Ma	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response)	l or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed.
Le Es Mo Ma	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE	I or pelvic surgery for CANCER stroke Routine, Once
Le Es Ma Lo [] ()	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE	l or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
Le Es Ma Lo [] () Ma	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE	l or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
Le Es Mc Ma [] () Mc Ac ph	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk	l or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
Le Es Mc Ma [] () Mc Ac ph	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated.	l or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
Le Es Mc Ma [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation Iowing. Mechanical prophylaxis is optional unless
Le Es Mc Ma [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	l or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation lowing. Mechanical prophylaxis is optional unless Routine, Once
Le Es Mc Ma [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation lowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once
Le Es Mc Ma Lo [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation lowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is
Le Es Mc Ma [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation lowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication
Le Es Mc Ma [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation Iowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following:
Le Es Mc Ma [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation lowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once
Le Es Mc Ma Lo [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation Iowing. Mechanical prophylaxis is optional unless Routine, Once Routin
Le Es Mc Ma Lo [] () Ma Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation Contraindications exist for pharmacologic prophylaxis	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation Iowing. Mechanical prophylaxis is optional unless Routine, Once
Le Es Mc Ma [] () Mc Ac ph [] []	ss than fully and independently ambulatory Acute ischemic s trogen therapy History of PE oderate or major surgery (not for cancer) ajor surgery within 3 months of admission w Risk of DVT Low Risk (Single Response) Low risk of VTE oderate Risk of DVT - Surgical Idress pharmacologic prophylaxis by selecting one of the fol armacologic prophylaxis is contraindicated. Moderate Risk Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	I or pelvic surgery for CANCER stroke Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation lowing. Mechanical prophylaxis is optional unless Routine, Once Routine, Once Routine, Once Routine, Once Routine, Once Routine, Once Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following

() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min

#### S+1 For Patients with CrCL LESS than 30 mL/min

S+1

40 mg, subcutaneous, daily at 0600 (time critical), Starting

30 mg, subcutaneous, daily at 0600 (time critical), Starting

() enoxaparin (LOVENOX) syringe

()	enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
() 1	fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily, Starting S+1</li> <li>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.</li> <li>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):</li> </ul>
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
, v	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
	lechanical Prophylaxis (Single Response)	
() (	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
• • •	Place/Maintain sequential compression device continuous	Routine, Continuous
	Place sequential compression device and antiembolic stockings	"And" Linked Panel
[]	Place/Maintain sequential compression device continuous	Routine, Continuous
[]	Place antiembolic stockings	Routine, Once
Add	lerate Risk of DVT - Non-Surgical ress pharmacologic prophylaxis by selecting one of the follo rmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
	Ioderate Risk	
[] M	Moderate risk of VTE Ioderate Risk Pharmacological Prophylaxis - Ion-Surgical Patient (Single Response)	Routine, Once
	Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
()	enoxaparin (LOVENOX) injection (Single Response)	
()	enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Startin S
()	enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Startin S For Patients with CrCL LESS than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl

<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min</li> </ul>	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl
	GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily</li> <li>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min</li> <li>This patient has a history of or suspected case of</li> </ul>
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
) High Risk of DVT - Surgical	
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCI GREATER than 30 mL/min</li> </ul>	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCI GREATER than 30 mL/min</li> </ul>	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl

() fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily, Starting S+1</li> <li>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.</li> <li>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):</li> </ul>
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
<ul> <li>heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li> </ul>	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
High Risk of DVT - Non-Surgical	
Address both pharmacologic and mechanical prophylaxis by orc ] High Risk	
	Routino Onco
I High risk of VTE           I High Risk Pharmacological Prophylaxis - Non-Surgical	Routine, Once
[] High risk of VTE	Routine, Once Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
<ul> <li>[] High risk of VTE</li> <li>] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)</li> </ul>	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.
<ul> <li>[] High risk of VTE</li> <li>] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)</li> <li>() Patient is currently receiving therapeutic anticoagulation</li> </ul>	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following
<ul> <li>[] High risk of VTE</li> <li>] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)</li> <li>() Patient is currently receiving therapeutic anticoagulation</li> <li>() Contraindications exist for pharmacologic prophylaxis</li> </ul>	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
<ul> <li>[] High risk of VTE</li> <li>] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)         <ul> <li>() Patient is currently receiving therapeutic anticoagulation</li> <li>() Contraindications exist for pharmacologic prophylaxis</li> <li>() enoxaparin (LOVENOX) injection (Single Response)</li> </ul> </li> </ul>	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 1700 (time critical), Startin
<ul> <li>[] High risk of VTE</li> <li>] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)</li> <li>() Patient is currently receiving therapeutic anticoagulation</li> <li>() Contraindications exist for pharmacologic prophylaxis</li> <li>() enoxaparin (LOVENOX) injection (Single Response)</li> <li>() enoxaparin (LOVENOX) syringe</li> <li>() enoxaparin (LOVENOX) syringe - For Patients with CrCL</li> </ul>	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 40 mg, subcutaneous, daily at 1700 (time critical), Startin S 30 mg, subcutaneous, daily at 1700 (time critical), Startin S

()	fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily</li> <li>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.</li> <li>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):</li> </ul>
$\overline{()}$	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
$\frac{O}{O}$	heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
()	with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[]	Mechanical Prophylaxis (Single Response)	
()	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
()	Place/Maintain sequential compression device continuous	Routine, Continuous
()	Place sequential compression device and antiembolic stockings	"And" Linked Panel
[]	Place/Maintain sequential compression device continuous	Routine, Continuous
_[]	Place antiembolic stockings	Routine, Once
[]	High Risk High risk of VTE	Routine, Once
	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	
()	Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
()	apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1
()		Indications:
()	aspirin chewable tablet	
$\left( \right)$	aspirin (ECOTRIN) enteric coated tablet	Indications:
() () ()	aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response)	Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1
() () () ()	aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) ) enoxaparin (LOVENOX) syringe - hip arthoplasty	Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Startin S+1
	aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) ) enoxaparin (LOVENOX) syringe - hip arthoplasty ) enoxaparin (LOVENOX) syringe - knee arthroplasty	Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Startin S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
	aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) ) enoxaparin (LOVENOX) syringe - hip arthoplasty	Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Startin S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
	<ul> <li>aspirin (ECOTRIN) enteric coated tablet</li> <li>enoxaparin (LOVENOX) injection (Single Response)</li> <li>enoxaparin (LOVENOX) syringe - hip arthoplasty</li> <li>enoxaparin (LOVENOX) syringe - knee arthroplasty</li> <li>enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty</li> </ul>	Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Startin S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Startin S+1

() fondaparinux (ARIXTRA) injection	<ul> <li>2.5 mg, subcutaneous, daily, Starting S+1</li> <li>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min</li> <li>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):</li> </ul>
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
<ul> <li>heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li> </ul>	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once

## Labs

### Labs STAT

[] CBC and differential	STAT For 1 Occurrences
[] Partial thromboplastin time	STAT For 1 Occurrences
[] POC occult blood stool and Notify	"And" Linked Panel
[] POC occult blood stool	Once
[] Notify Physician If occult stool is positive.	Routine, Until discontinued, Starting S
Antithrombin III	STAT For 1 Occurrences
Cardiolipin antibody	STAT For 1 Occurrences
[] Factor V assay	STAT For 1 Occurrences
] Factor V leiden	STAT For 1 Occurrences
] Homocystine, plasma	STAT For 1 Occurrences
] Lupus anticoagulant	STAT For 1 Occurrences
Protein C activity	STAT For 1 Occurrences
Protein S activity	STAT For 1 Occurrences
Prothrombin gene mutation	STAT For 1 Occurrences

Labs Tomorrow

[] CBC and differential	AM draw For 1 Occurrences
[] Partial thromboplastin time	AM draw For 1 Occurrences
[] Comprehensive metabolic panel	AM draw For 1 Occurrences

Labs AM Repeat

[] CBC and differential	AM draw repeats For 3 Occurrences
[] Partial thromboplastin time	AM draw repeats For 3 Occurrences
[] Prothrombin time with INR	AM draw repeats For 3 Occurrences

## Cardiology

## Imaging

#### СТ

[] CT Angiogram Pe Chest

Routine, 1 time imaging For 1 PE Protocol

X-Ray

[] Chest 1 Vw Portable	Routine, 1 time imaging For 1 Occurrences
[] Chest 2 Vw	Routine, 1 time imaging For 1 Occurrences

#### **US for DVT Diagnosis**

[] PV duplex venous lower extremity bilat	Routine, 1 time imaging	
[] PV duplex venous lower extremity left	Routine, 1 time imaging	
[] PV duplex venous lower extremity right	Routine, 1 time imaging	
[] PV duplex venous upper extremity bilat	Routine, 1 time imaging	
[] PV duplex venous upper extremity left	Routine, 1 time imaging	
[] PV duplex venous upper extremity right	Routine, 1 time imaging	

US

[] USPV Venous Lower Extremity Bilateral	Routine, 1 time imaging For 1
[] USPV Venous Lower Extremity Left	Routine, 1 time imaging For 1
[] USPV Venous Lower Extremity Right	Routine, 1 time imaging For 1
[] USPV Venous Upper Extremity Bilat	Routine, 1 time imaging For 1
[] USPV Venous Upper Extremity Left	Routine, 1 time imaging For 1
[] USPV Venous Upper Extremity Right	Routine, 1 time imaging For 1

Nuclear

[] NM Lung Ventilation Perfusion

Routine, 1 time imaging For 1

# Other Studies

Respiratory

### Rehab

### Consults

For Physician Consult orders use sidebar

#### **Ancillary Consults**

Consult Reason:	
Reason for Consult:	
Special Instructions:	
Weight Bearing Status:	
Special Instructions:	
Weight Bearing Status:	
Reason For Consult? Other (Specify)	
Specify: Low vitamin K diet	
Reason for consult?	
Reason for Consult?	
	Reason for Consult:         Special Instructions:         Weight Bearing Status:         Special Instructions:         Weight Bearing Status:         Reason For Consult? Other (Specify)         Specify: Low vitamin K diet         Reason for consult?

## Additional Orders